Der var ingen klinisk relevante forskelle i sikkerhedspopulationen af de ældre forsøgspersoner, som fik oseltamivir eller placebo, sammenlignet med voksenpopulationen i alderen op til 65 år.
There were no clinically relevant differences in the safety population of the elderly subjects who received oseltamivir or placebo compared with the adult population aged up to 65 years.